<DOC>
	<DOCNO>NCT00695669</DOCNO>
	<brief_summary>The purpose study characterize immunogenicity &amp; safety 2 dose GSK 's avian flu vaccine GSK 1557484A give accord different regimen adult age 18 64 year</brief_summary>
	<brief_title>A Trial Test Response Different Vaccination Regimens With H5N1 Vaccine With AS03 Adults Aged 18-64</brief_title>
	<detailed_description>A Phase 2 , open-label , randomize , parallel group , multi-centered study design evaluate immunogenicity safety 2-dose series avian influenza vaccine plus AS03 adjuvant accord different regimen , adult age 18-64 year . All subject receive active study vaccine ; subject receive placebo . A total 312 subject enrol study approximately 3 study center Canada . All subject attend formal study center visit safety immunogenicity assessment Days 0 , 21 , 42 , 182 . Additional formal study center visit schedule additional timepoints subject particular dose group . In addition , telephone call conducted subject Day 51</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>A male female 1864 year old time first vaccination . Written inform consent obtain subject . Good general health establish medical history clinical examination enter study . Access consistent mean telephone contact . Comprehension study requirement , ability comprehend comply procedure collection short longterm safety data , express availability require study period , ability willingness attend schedule visit . Subjects investigator believe comply requirement protocol enrol study Presence evidence substance abuse neurological psychiatric diagnosis , even clinically stable , deemed investigator render potential subject unable/unlikely provide accurate safety report . Diagnosed cancer , treatment cancer , within 3 year . Persons history cancer diseasefree without treatment 3 year eligible . Persons history histologicallyconfirmed basal cell carcinoma skin successfully treat local excision except may enrol , histological type skin cancer exclusionary . Women diseasefree 3 year treatment breast cancer receive longterm prophylactic tamoxifen except may enrol . Presence oral temperature ≥37.8ºC , acute symptom great `` mild '' severity schedule date first vaccination . Any confirm suspected immunosuppressive immunodeficient condition include history human immunodeficiency virus ( HIV ) infection . Receipt systemic glucocorticoid within 1 month study enrollment , cytotoxic immunosuppressive drug within 6 month study enrollment . Any significant disorder coagulation treatment Coumadin derivatives heparin . Administration vaccine within 30 day study enrollment 30 day follow last test article dose . Subjects receive immunization emergent basis enrollment follow per protocol include Total Vaccinated Cohort ( TVC ) , exclude According Protocol ( ATP ) Cohort safety immunogenicity . Previous administration H5N1 vaccine . Use investigational nonregistered product ( drug vaccine ) plan participation another investigational study within 30 day prior study enrollment , 182 day follow first test article dose . Use investigational nonregistered product immunosuppressive property exclusionary time trial . Receipt immunoglobulins and/or blood product within 6 month study enrollment plan administration product study period . Any known suspected allergy constituent influenza vaccine ( include egg proteins mercurial preservative ) ; history anaphylactictype reaction consumption egg ; history severe adverse reaction previous influenza vaccine . Known pregnancy positive urine betahuman chorionic gonadotropin ( βhCG ) test result prior either vaccination . Lactating nursing . Women child bear potential lack history reliable contraceptive practice . The provision history NOT replace requirement perform , obtain negative result pregnancy urine test prior treatment . Note : woman urine pregnancy test regardless status . Known receipt analgesic antipyretic medication day treatment specific intent prophylaxis vaccine reactogenicity day first treatment . Subjects stable chronic regimen potentially analgesic antipyretic medication preexist diagnosis require discontinue</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>H5N1</keyword>
	<keyword>immunogenicity</keyword>
	<keyword>influenza</keyword>
	<keyword>Avian</keyword>
	<keyword>pandemic</keyword>
	<keyword>vaccine</keyword>
	<keyword>human</keyword>
	<keyword>safety</keyword>
</DOC>